Advertisement


Michael Kenneth Keng, MD, on an ASCO Quality Training Program: 5-Year Review

2019 Quality Care Symposium

Advertisement

Michael Kenneth Keng, MD, of the University of Virginia, gives a status update on this international program, and discusses future initiatives which include coaching mentorship and publishing articles on quality care (Abstract 7).



Related Videos

Issues in Oncology

Matthew B. Schabath, PhD, on Addressing Cultural Barriers to Equality in Oncology Among Sexual and Gender Minorities

Matthew B. Schabath, PhD, of H. Lee Moffitt Cancer Center and Research Institute, discusses the disparities in cancer care among members of the LGBTQ community and the need to collect more data in order to close that gap.

Supportive Care
Cost of Care

Linda D. Bosserman, MD, on Pathways for Personalized Precision Medicine and Value

Linda D. Bosserman, MD, of City of Hope, discusses guidelines vs pathways, how to personalize pathways, integrated diagnostics, supportive care regimens, and financial guidance for patients with cancer.

Issues in Oncology
Health-Care Policy

Karen M. Winkfield, MD, PhD, on Policy and Business Solutions to Address Disparities in Cancer Care

Karen M. Winkfield, MD, PhD, of the Wake Forest Baptist Medical Center, discusses cultural factors that contribute to cancer care disparities, the role of national policy in addressing inequities in access to care, and what local institutions can do to improve the situation.

Issues in Oncology

Nadine Housri, MD, on Online Tumor Boards: A New Resource for Practicing Oncologists

Nadine Housri, MD, of the Yale School of Medicine, talks about a new paradigm in sharing knowledge from tumor board discussions at NCI-designated comprehensive cancer centers, with community oncologists on themednet.org. Currently, thoracic, breast, and GI cancers are included, with plans to expand the scope (Abstract 272).

Lung Cancer

Cristina Merkhofer, MD, MHS, on NSCLC: Survival Impact of Taking Part in a Clinical Trial

Cristina Merkhofer, MD, MHS, of Fred Hutchinson Cancer Research Center, discusses study results showing that for patients with metastatic non–small cell lung cancer at her institution, enrolling in a therapeutic drug clinical trial was associated with a 47% lower risk of death, compared with not taking part in a trial (Abstract 137).

Advertisement

Advertisement




Advertisement